Regulatory FDA delays verdict on AZ breast cancer drug PharmaphorumAfter an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.OncologyRead full story pharminent May 27, 2026 (Last updated: May 27, 2026) Pharmaphorum After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer. Oncology Read full story Post navigation Previous: Early data for heart drug affirm Lilly’s billion-dollar bet on VerveNext: Kardigan targets IPO to support cardiology pipeline progression Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026